For a number of years it has been suggested that inhibiting myostatin could be a treatment for degenerative muscle diseases such as DMD, although experimental evidence has been conflicting.

The challenge of the obesity epidemic is widespread and one that even pediatricians face constantly,” a Connecticut doctor said.

The prospects of a new class of Duchenne muscular dystrophy therapies have taken another downturn after Roche abandoned development of RG6206, a myostatin inhibitor. The Swiss group revealed the ...

A trial found magnetic resonance imaging correlated with physical function tests in patients with Duchenne muscular dystrophy ...

Apitegromab, a fully human monoclonal antibody, works by selectively binding to the pro- and latent forms of myostatin in order to inhibit myostatin activation. This binding is expected to improve ...

Myostatin inhibitors, designed to promote muscle growth, are being developed for the treatment of muscular dystrophy, among other disorders. Pharmaceutical companies are also examining whether these ...

One of the standout ingredients is Epicatechin, derived from the Camellia sinensis plant, known for its ability to inhibit myostatin— a protein that limits muscle growth. By reducing myostatin ...

have recently been testing myostatin inhibitors in phase three trials in patients with spinal muscular atrophy, or SMA, a rare neuromuscular disease “with devastating consequences.” ...